• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Home
  • LinkedIn
  • Twitter

  • About Us
    • Overview
    • Executive Committee
    • Board Of Directors
  • Newsroom
    • Scientific Publications
    • Press Releases
    • Events
  • Partnering
  • Investors
    • Overview
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Contact Us

Home

ABOUT CELYAD ONCOLOGY

Celyad Oncology is a biotechnology company focused primarily on unlocking the potential of its intellectual property.

More Info About Celyad ONCOLOGY

Latest News

376_981be

Publication of a transparency notification received from Tolefi SA (Article 14§1 of the Law of 2 May 2007)

July 28, 2026
READ THE PRESS RELEASE about Publication of a transparency notification received from Tolefi SA (Article 14§1 of the Law of 2 May 2007)

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

July 22, 2026
READ THE PRESS RELEASE about Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Celyad Oncology Announces €500,000 Private Placement

July 14, 2026
READ THE PRESS RELEASE about Celyad Oncology Announces €500,000 Private Placement

Celyad Oncology reports full year 2025 financial results and business highlights

April 2, 2026
READ THE PRESS RELEASE about Celyad Oncology reports full year 2025 financial results and business highlights

Celyad Oncology Announces the sale of C-CATHez® Catheter

February 12, 2026
READ THE PRESS RELEASE about Celyad Oncology Announces the sale of C-CATHez® Catheter

Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)

November 25, 2025
READ THE PRESS RELEASE about Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

November 14, 2025
READ THE PRESS RELEASE about Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Celyad Oncology Announces Research Facility Divestiture

September 29, 2025
READ THE PRESS RELEASE about Celyad Oncology Announces Research Facility Divestiture

Celyad Oncology reports first half year 2025 financial results

September 25, 2025
READ THE PRESS RELEASE about Celyad Oncology reports first half year 2025 financial results

Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)

September 11, 2025
READ THE PRESS RELEASE about Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)
Discover All News

Our strategy

Our differentiated strategy includes the development of technology platforms and CAR T-cell candidates to broaden the range of cancer indications and tackle the main limitations of current CAR T-cell therapies

Read More About Our SCIENCE
Artwork of lymphocytes.

Stay informed about the latest news!

Sign up FOR our newsletter



    By clicking on “send”, you consent that your personal data will be processed by us in order to send you our newsletter. You have the right to access, rectify, erase your data, to restrict the processing and the right to withdraw your consent at any time. You can find more information on how we process your data in our Privacy Policy.

    Footer

    Celyad Oncology

    Celyad Oncology Logo
    • About
    • Newsroom
    • Partnering
    • Investors
    • Contact Us
    • LinkedIn
    • Twitter

    Copyright © 2026 All Rights Reserved.

    • Cookie Policy |
    • Privacy Policy |
    • Terms of Use